statistiche ricercatore

Nazione	#
FI - Finlandia	1.893
US - Stati Uniti d'America	667
SG - Singapore	198
CN - Cina	102
IT - Italia	90
BR - Brasile	71
VN - Vietnam	62
PL - Polonia	47
DE - Germania	42
TW - Taiwan	40
HK - Hong Kong	39
GB - Regno Unito	26
FR - Francia	17
JP - Giappone	15
RU - Federazione Russa	14
ID - Indonesia	13
TR - Turchia	11
IN - India	10
CA - Canada	9
UA - Ucraina	9
SE - Svezia	8
AT - Austria	6
BE - Belgio	6
CO - Colombia	6
MX - Messico	6
NL - Olanda	6
AR - Argentina	5
BD - Bangladesh	5
DK - Danimarca	5
EG - Egitto	5
ES - Italia	5
ZA - Sudafrica	5
ET - Etiopia	4
IQ - Iraq	4
AL - Albania	3
EC - Ecuador	3
JO - Giordania	3
KE - Kenya	3
VE - Venezuela	3
LT - Lituania	2
MY - Malesia	2
PK - Pakistan	2
PY - Paraguay	2
RO - Romania	2
TN - Tunisia	2
UZ - Uzbekistan	2
AE - Emirati Arabi Uniti	1
AZ - Azerbaigian	1
BA - Bosnia-Erzegovina	1
BB - Barbados	1
CH - Svizzera	1
CR - Costa Rica	1
CY - Cipro	1
CZ - Repubblica Ceca	1
DZ - Algeria	1
EE - Estonia	1
GR - Grecia	1
HU - Ungheria	1
IS - Islanda	1
KW - Kuwait	1
KZ - Kazakistan	1
LB - Libano	1
LV - Lettonia	1
MA - Marocco	1
MU - Mauritius	1
SD - Sudan	1
SK - Slovacchia (Repubblica Slovacca)	1
TH - Thailandia	1
TT - Trinidad e Tobago	1
Totale	3.503

Nome	#
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: Final results of the phase III randomized Short-HER study	2.076
High-sensitivity assay for monitoring ESR1 mutations in circulating cell-free DNA of breast cancer patients receiving endocrine therapy	291
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial	270
Core needle biopsy in invasive breast cancer prognostic/predictive power: concordance with surgical speciemen and impact of immunophenotypes	202
ErbB2‐NOTCH1 axis controls autophagy in cardiac cells	153
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study	153
The Value of Semiquantitative Parameters Derived from 18F-FDG PET/CT for Predicting Response to Neoadjuvant Chemotherapy in a Cohort of Patients with Different Molecular Subtypes of Breast Cancer	146
Impact on the long-term prognosis of FDG PET/CT in luminal-A and luminal-B breast cancer	126
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)	116
Totale	3.533

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	51	0	0	0	0	0	0	0	0	0	27	17	7
2021/2022	54	4	8	5	3	1	1	7	3	2	5	3	12
2022/2023	76	8	8	3	7	8	10	5	11	10	1	5	0
2023/2024	76	1	12	4	1	7	11	2	2	1	6	16	13
2024/2025	308	6	12	23	11	30	30	10	14	57	28	45	42
2025/2026	2.710	87	41	64	85	128	70	114	79	1.946	96	0	0
Totale													3.533

SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara